menu

Psychotic Symptoms in Parkinson’s Disease Psychosis Disrupts Lives: Early Treatment Intervention Makes a Difference

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Parkinson’s Disease Psychosis: Anchoring Reality Through Novel Therapeutic Paradigms

Psychotic Symptoms in Parkinson’s Disease Psychosis Disrupts Lives: Early Treatment Intervention Makes a Difference

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including Neurologists, Psychiatrists, Primary Care Physicians, Nurses, Nurse Practitioners, Pharmacists, and Physician Assistants,as well as other clinicians involved in the management of patients with Parkinson’s Disease Psychosis (PDP).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Learn to integrate routine screening of all patients with Parkinson’s disease to recognize the signs and symptoms of Parkinson's Disease Psychosis (PDP) earlier
    • Select an appropriate treatment option for the management of patients with PDP based upon the available evidence-based clinical safety and efficacy data, MDS guidelines, and expert consensus
    • Develop an individualized, evidence-based, patient-centric care plan for persons that improve the quality of life and outcome in people suffering from PDP
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Rajesh Pahwa, MD, chair for this educational event, receives research funds from Abbott, AbbVie, Alexza, Annovis, Biogen, Bluerock, Bukwang, Cerevel, Global Kinetics, Jazz, Michael J Fox Foundation, Neuroderm, Neuraly, Parkinson’s Foundation, Praxis, Roche, Sage, Scion, Sun Pharma, UCB, and Voyager; and receives consulting fees from Abbott, AbbVie, ACADIA, Acorda, Allevion, Amneal, Artemida, BioVie, CalaHealth, Convatec, Global Kinetics, Inbeeo, Insightec, Jazz, Kyowa, Lundbeck, Merz, Neurocrine, Neuroderm, Ono, PhotoPharmics, Sage, Sunovion, Supernus, UCB and Wren. 

    Daniel Kremens, MD, JD, faculty for this educational event, receives consulting fees from Teva Pharmaceuticals, Sunovion, Amneal, Avion, Lundbeck, Acadia, USWorldMeds, Supernus, Adamas, Abbvie, Merz, Allergan, Acorda, Kyowa Kirin, Neurocrine, Supernus and Britannia; and receives research funds from Voyager Therapeutics, Revance and Enterin.    

    Stuart Isaacson, MD, faculty for this educational event, receives research support from Abbvie, Acadia, Acorda, Adamas, Addex, Amneal, Aptinyx, Axial, Benevolent, Biogen, Biovie, Cadent, Cala, Cerecor, Cerevel, Eli Lilly, Enterin, Global Kinetics, Impax, Intec Pharma, Jazz, Kyowa Kirin, Lundbeck, Michael J. Fox Foundation, Neuralys, Neurocrine, Neuroderm, Novartis, Parkinson Study Group, Pharma2B, Praxis, Prilenia, Revance, Roche, Sage, Sanofi, Scion, Stoparkinson, Sunovion, Sun Pharma, Supernus, Teva, Theravance, Transposon and UCB; and receives consulting fees from Abbvie, Acadia, Acorda, Adamas, Addex, Affiris, Alexza, Allergan, Amneal, Britannia, Cala, Cerecor, Cerevel, Enterin, GE Healthcare, Global Kinetics, Impax, Impel, Kyowa Kirin, Lundbeck, Merz, Neurocrine, Neuroderm, Pharma2B, Revance, Roche, Sage, Scion Neurostim, Stoparkinson, Sunovion, Supernus, Teva and UCB.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Canan Schumann, PharmD/PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Acadia Pharmaceuticals Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statements

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 4/28/2023 through 4/28/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Oct 2023